GILD - Gilead Sciences, Inc.
| Previous Close | 68.65 |
| Open | 69.24 |
| Bid | 69.24 x 2200 |
| Ask | 69.39 x 900 |
| Day's Range | 68.51 - 69.58 |
| 52 Week Range | 60.32 - 89.54 |
| Volume | 8,358,808 |
| Avg. Volume | 7,885,491 |
| Market Cap | 89.493B |
| Beta (3Y Monthly) | 1.34 |
| PE Ratio (TTM) | 57.41 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.28 (3.37%) |
| Ex-Dividend Date | 2018-12-13 |
| 1y Target Est | N/A |
- Motley Fool•2 days ago
Better Buy: Biogen vs. Gilead Sciences
Which stock wins in a battle between these two big biotechs?
- Markit•2 days ago
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
# Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $7.20 billion over the last one-month into ETFs that hold GILD are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Investor's Business Daily•3 days ago
These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts
Biotech stocks Gilead Sciences, Biogen and Celgene are set to beat some aspects of Q4 earnings estimates, an analyst predicted, saying he expects conservative guidance.
- Benzinga•3 days ago
Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year
Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation of fat in the liver of people who do not consume alcohol. NAFLD is a less serious condition, although non-alcoholic steatohepatitis, or NASH — a subset of NAFLD — is life-threatening, given its potential to cause liver scarring and cirrhosis. NAFLD affects about 80-100 million people in the U.S. alone — roughly 25 percent of the total population.
Motley Fool•4 days ago1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet)
Revenue growth is key.
- Motley Fool•4 days ago
Why Gilead Sciences Stock Sank by 12.7% in 2018
Gilead's stock churned lower yet again last year, but the biotech could finally be nearing an inflection point.
- Zacks•4 days ago
Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon
- Markit•4 days ago
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
# Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $9.02 billion over the last one-month into ETFs that hold GILD are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•5 days ago
Will Dividend Stocks be the Hot Stocks of 2019?
With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.
- Zacks•6 days ago
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Gilead Sciences (GILD) closed at $68.52 in the latest trading session, marking a +1.89% move from the prior day.
- Investor's Business Daily•6 days ago
Here's How The Government Shutdown Will Affect These Medical Stocks
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
- Motley Fool•10 days ago
Here's Why Verastem Tumbled 34.1% in December
Investors have been worried about a difficult new drug launch.
- Zacks•10 days ago
NASH Space in Focus in 2019 as Firms Look to Diversify
NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.
- Simply Wall St.•12 days ago
Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
- Kiplinger•12 days ago
Value Added: 7 Top Stocks for 2019
Making money in the stock market this year is going to take all the skill and luck you can muster. The global economy is slowing, a trade war with China still lingers despite negotiations, and the Federal Reserve remains likely to raise short-term interest rates, albeit slowly. But you still can find promising investments. To identify some of the top stocks right now, I interviewed Jerome Dodson, manager of Parnassus Endeavor Fund (PARWX) and founder of the Parnassus funds. Based in San Francisco, Parnassus is the largest U.S. fund firm focused on buying good stocks that are also, in the firm's view, good corporate citizens in terms of the environment, social and corporate governance issues. More to the point, Dodson's fund has a first-class record. Endeavor returned an annualized 16.3% over the past 10 years - an average of 3.1 percentage points per year better than the Standard & Poor's 500-stock index. Dodson, 75, is a contrarian investor who loves to pounce on stocks that have been pummeled. Given the selloff, this is precisely Dodson's kind of market. Read on for his seven top stocks for 2019. ### SEE ALSO: 19 Best Retirement Stocks to Buy in 2019
- Zacks•12 days ago
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
- American City Business Journals•12 days ago
Cell therapy pioneer eyes Bay Area manufacturing
The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
# Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Kiplinger•13 days ago
The 9 Best Stocks of America’s Last Bear Market
It's official. The Nasdaq Composite has waded all the way into bear-market territory, now down 20% from its late-September peak. The Dow Jones Industrial Average and the Standard & Poor's 500-stock index aren't far behind. Whether the fourth-quarter selloff is merited doesn't entirely matter. If the crowd believes the rout suffered over the course of the past three months is the shape of things to come, stocks will lose more ground as investors create the very bear market they fear. It's a self-fulfilling prophecy. But here at the precipice of seeing the market's condition shift from bad to worse, remember: Not all stocks have to lose ground, even if the tide is going out. One only has to look at the nine big stocks that managed to gain ground between October 2007 and March 2009 - America's last bear market - to appreciate that some companies have staying power even in rough environments. Here are nine S&P; 500 stocks that actually gained in the face of the 2007-09 bear market. Notice in all nine cases, there was something unique about these organizations that shielded them from the full impact of economic woe. And in some cases, they still look properly positioned to fight off another bear attack. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
- Investing.com•13 days ago
Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close
Investing.com - Union Pacific , Motorcar Parts of America and Nektar Therapeutics surged on Tuesday, underpinning a second-straight day of gains in the broader market.
- Markit•13 days ago
See what the IHS Markit Score report has to say about Gilead Sciences Inc.
# Gilead Sciences Inc ### NASDAQ/NGS:GILD View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, ETFs holding GILD are favorable, with net inflows of $20.43 billion. Additionally, the rate of inflows is increasing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•13 days ago
7 Things to Expect for Gilead Sciences in 2019
The big biotech's executives spill the beans on plans for the new year at the J.P. Morgan Healthcare Conference.
- Zacks•14 days ago
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD) closed at $68.56 in the latest trading session, marking a +0.45% move from the prior day.
- American City Business Journals•14 days ago
Biotech's big conference living up to reputation with big deals, big costs
Deals are rolling out during the first day of the J.P. Morgan Healthcare Conference and so, too, are the hotel meeting costs.
- Motley Fool•14 days ago
Why Agenus Stock Is Spiking Today
Eli Lilly's acquisition of Loxo Oncology lit a fire underneath the cancer immunotherapy company today..
